ASCO Genitourinary Cancers Symposium (ASCO-GU) 2021

Exploratory gene-by-gene analysis of olaparib efficacy in patients with metastatic castration-resistant prostate cancer: PROfound

Feasibility and clinical utility of circulating tumor DNA testing for BRCA/ATM alternations to assess olaparib efficacy in patients with metastatic castration-resistant prostate cancer Exploratory analyses form the PROfound study

A phase 3 trial of capivasertib and abiraterone versus placebo and abiraterone in patients with de novo metastatic hormonesensitive prostate cancer characterized by PTEN deficiency (CAPItello-281)

A phase 1 study of capivasertib in combination with abiraterone acetate in patients with metastatic castration-resistant prostate cancer